WEST BEND, Wis., Sept. 12, 2011 /PRNewswire/ —
Frontage Laboratories, Inc., a global full-service Clinical
Research Organization with facilities in the US and China, and
Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical
Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer
have entered into a strategic partnership agreement. This
synergistic and cost-effective partnership establishes a global
footprint by combining Frontage’s presence in China and its
expertise in drug formulation and Bioanalytical analysis, along
with Spaulding Clinical’s Cardiac Safety and fully-automated
Clinical Pharmacology facility.
As part of the relationship, Spaulding Clinical will perform all
intense electrocardiographic studies in its facility and provide
ECG Core Lab services on behalf of Frontage. In return,
Frontage will provide bioanalytical method development and sample
processing, formulation development and clinical trial product
supplies for Spaulding Clinical, as well as serve as one of the
clinical sites for Spaulding Clinical clients in China.
“Throughout the due diligence process, we were thoroughly
impressed with the innovative, quality-focused clinical conduct we
witnessed at Spaulding,” states Song Li, PhD, CEO and Chairman of
Frontage Laboratories, Inc. “The collaboration with Spaulding
Clinical will enable Frontage to better service our current and
potential clients in a more comprehensive approach, especially in
the areas of cardiac safety, thorough QT, and ECG Core Lab.”
Randy Spaulding, CEO and Founder of Spaulding Clinical, states,
“This collaboration represents another step forward in meeting our
strategic objectives of providing the highest quality global
clinical development facilities to our clients interested in
accelerating drug development. Together, Frontage and
Spaulding Clinical will deliver the first US-based fully-automated
Clinical Pharmacology unit in China.”
‘/>”/>
